GHRS
GH Research PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$910.59M
P/E Ratio
—
EPS
$-0.77
Beta
1.00
52W High
$19.51
52W Low
$8.22
50-Day MA
$15.17
200-Day MA
$14.23
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About GH Research PLC
GH Research PLC is a cutting-edge clinical-stage biopharmaceutical company focused on developing transformative psilocybin-based therapies for psychiatric and neurodegenerative disorders. With a promising pipeline of drug candidates, the company aims to fulfill significant unmet needs in mental health care, leveraging the expertise of a skilled team committed to advancing scientific innovation. GH Research's pioneering initiatives are set to redefine treatment paradigms and enhance patient outcomes, establishing it as a potential leader in the rapidly evolving field of mental health therapeutics.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-60.60M |
| Operating Margin | 0.00% |
| Return on Equity | -21.00% |
| Return on Assets | -15.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.51 |
| Price-to-Book | 3.22 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.97 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $62.03M |
| Float | $22.82M |
| % Insiders | 26.78% |
| % Institutions | 74.93% |
Analyst Ratings
Consensus ($39.25 target)
3
Strong Buy6
BuyData last updated: 4/8/2026